Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Olema Pharmaceuticals, Inc. (OLMA) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "Amendment No. 1 to Amended and Restated Clinical Collaboration and Supply Agreement, by and between the Company and Novartis Institutes for BioMedical Research, Inc.",
"# # #"
10/03/2023 4 Harmon Cyrus (Director) has filed a Form 4 on Olema Pharmaceuticals, Inc.
Txns: Sold 25,000 shares @ $12.41, valued at $310.3k
09/29/2023 144 Form 144 - Report of proposed sale of securities:
08/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/16/2023 144 Form 144 - Report of proposed sale of securities:
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
07/20/2023 144 Form 144 - Report of proposed sale of securities:
07/18/2023 144 Form 144 - Report of proposed sale of securities:
06/29/2023 144 Form 144 - Report of proposed sale of securities:
06/28/2023 144 Form 144 - Report of proposed sale of securities:
06/12/2023 144 Form 144 - Report of proposed sale of securities:
06/09/2023 144 Form 144 - Report of proposed sale of securities:
06/09/2023 4 Harmon Cyrus (Director) has filed a Form 4 on Olema Pharmaceuticals, Inc.
Txns: Sold 10,000 shares @ $6.3, valued at $63k
06/08/2023 144 Form 144 - Report of proposed sale of securities:
06/08/2023 144 Form 144 - Report of proposed sale of securities:
06/07/2023 4 Harmon Cyrus (Director) has filed a Form 4 on Olema Pharmaceuticals, Inc.
Txns: Sold 5,000 shares @ $6.045, valued at $30.2k
Sold 5,000 shares @ $6.295, valued at $31.5k
06/06/2023 144 Form 144 - Report of proposed sale of securities:
06/06/2023 144 Form 144 - Report of proposed sale of securities:
06/05/2023 144 Form 144 - Report of proposed sale of securities:
06/05/2023 144 Form 144 - Report of proposed sale of securities:
05/19/2023 144 Form 144 - Report of proposed sale of securities:
05/11/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "# # #",
" $&+&2$$ #)$# $#)#)"#) )$ )  '+) *'))$# $'" -) $ BJJF3 ))"#))$# )) ' #$) )"#)$'! ) ' $','8!$$ # )"#))"#)$*) !"))$#0 )"#) %!# #) $' #. $)' *)*' %'$*) #) "&#x..."
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
03/29/2023 144 Form 144 - Report of proposed sale of securities:
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/09/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/09/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/09/2023 10-K Annual Report for the period ended December 31, 2022
03/09/2023 8-K Quarterly results
02/14/2023 SC 13G/A Fairmount Funds Management LLC reports a 0% stake in Olema Pharmaceuticals, Inc.
02/14/2023 SC 13G/A Cormorant Asset Management, LP reports a 5.2% stake in Olema Pharmaceuticals, Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy